Our results showed that c-Met overexpression was independent of hormone receptor status and there was no statistical significance of c-Met overexpression between TNBC and non-TNBC group, which indicated that c-Met could be a target for breast cancer regardless of hormone status. The gene discussed is NR4A1; the disease is breast carcinoma.